Alnylam Pharmaceuticals
ALNY
#434
Rank
ยฃ39.93 B
Marketcap
ยฃ302.31
Share price
-2.59%
Change (1 day)
52.16%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): ยฃ0.05839

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is ยฃ0.06727. In 2023 the company made an earnings per share (EPS) of -ยฃ2.64 an increase over its 2022 EPS that were of -ยฃ6.94.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)ยฃ0.05839
2023-ยฃ2.64-62%
2022-ยฃ6.9429.03%
2021-ยฃ5.38-3.36%
2020-ยฃ5.57-8.48%
2019-ยฃ6.087.67%
2018-ยฃ5.6539.74%
2017-ยฃ4.0412.94%
2016-ยฃ3.5838.84%
2015-ยฃ2.58-32.88%
2014-ยฃ3.84259.44%
2013-ยฃ1.07-31.25%
2012-ยฃ1.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-ยฃ0.93-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
ยฃ32.47 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ2.05-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.18-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ0.55-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
ยฃ5.50 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ2.77 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
ยฃ0.47 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel